Akebia Therapeutics (AKBA) EBITDA Margin Growth (1y) (2018 - 2026)
Akebia Therapeutics (AKBA) EBITDA Margin Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1,647.00 |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -368.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -17.00 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -341.00 |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -634.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -538.00 |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 40.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -3,474.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,543.00 |
| Mar 31, 2026 | -3,234.00 |
| Dec 31, 2025 | 1,593.00 |
| Sep 30, 2025 | 4,098.00 |
| Jun 30, 2025 | 4,254.00 |
| Mar 31, 2025 | 6,938.00 |
| Dec 31, 2024 | -3,321.00 |
| Sep 30, 2024 | -241.00 |
| Jun 30, 2024 | -403.00 |
| Mar 31, 2024 | 1,818.00 |
| Dec 31, 2023 | 1,117.00 |
| Sep 30, 2023 | 7,247.00 |
| Jun 30, 2023 | -4,292.00 |
| Mar 31, 2023 | 7.83 Mn |
| Dec 31, 2022 | -5,169.00 |
| Sep 30, 2022 | 910.00 |
| Jun 30, 2022 | 17,691.00 |
| Mar 31, 2022 | -7.83 Mn |
| Dec 31, 2021 | 42,949.00 |
| Sep 30, 2021 | 27,473.00 |